The Wall Street Journal 
(7/6, Dooren, Subscription Publication) reports that the Food and Drug
Administration yesterday approved Roche Holding's COBAS AmpliPrep/COBAS
TaqMan CMV Test, to aid physicians in tracking cytomegalovirus (CMV). A
result showing a decline in the virus would indicate a successful
treatment, while an increase would indicate that a different treat
should be tried. The virus is common and is frequently found in
patients with transplanted organs.
(7/6, Dooren, Subscription Publication) reports that the Food and Drug
Administration yesterday approved Roche Holding's COBAS AmpliPrep/COBAS
TaqMan CMV Test, to aid physicians in tracking cytomegalovirus (CMV). A
result showing a decline in the virus would indicate a successful
treatment, while an increase would indicate that a different treat
should be tried. The virus is common and is frequently found in
patients with transplanted organs.
Reuters
(7/6, Siddiqui) reports the test is for use on organ transplant
patients being treated for CMV. The FDA said that the test cannot be
used to diagnose CMV infection.
(7/6, Siddiqui) reports the test is for use on organ transplant
patients being treated for CMV. The FDA said that the test cannot be
used to diagnose CMV infection.
No comments:
Post a Comment